melanoma

New models for patient care: advanced pharmacy practitioners

Treatment options for mucosal melanoma patients

KEYNOTE-006: the efficacy of ipilimumab after pembrolizumab in patients with advanced melanoma

Preventing melanoma through public health education

Oncolytic virus therapy in the treatment of melanoma

Role of BRAF mutation in the treatment for melanoma

Immunotherapy and targeted therapies for melanoma

Current clinical perspectives on targeted therapy and immunotherapy for melanoma

Clinical developments in the treatment for melanoma

Aggressive care at the end-of-life for younger cancer patients: ASCO’s Choosing Wisely campaign

Global differences in cancer drug prices: a comparative analysis

Targeted therapy for advanced solid tumors based on molecular profiles: early results from MyPathway

ASCO 2016 highlights for immunotherapy

Influence of new immunotherapy checkpoint inhibitors in melanoma

Targeting RAS oncogenes in patients with NRAS-mutated melanoma

OS rates and prognostic categories for BRAF-mutated melanoma when treated with combination therapy